Bringing innovative value to healthy human life

Convalife Pharmaceuticals is a clinical-stage new drug research and development enterprise based in China and facing the world. It is committed to developing innovative drugs in the fields of oncology, viruses and aging diseases. The core team of Convalife Pharmaceuticals is mainly from top domestic and foreign pharmaceutical companies such as Novartis and Huahai, and continues to cooperate with well-known domestic and foreign research institutes such as Shanghai Institute of Pharmacy, Chinese Academy of Sciences. Guided by the unmet clinical drug needs in China and the world, the company designs and develops original new drugs with "First-in-Class" or "Best-in-Class" potential, distributes a new generation of bispecific antibody biological drugs and differentiated small molecule drugs, and provides innovative treatment programs for the majority of patients. Convalife Pharmaceuticals' oncology product pipeline covers solid tumors and hematological tumors that are in urgent need of innovative treatment options at home and abroad, such as breast cancer, lung cancer, cholangiocarcinoma, prostate cancer, pancreatic cancer, gastric cancer, etc., including the second-generation PARP inhibitor CVL218, which has shown the potential of "Best-in-Class", the world's leading PI3Kβ/δ dual highly selective inhibitor CVL237, and the "First-in-Class" innovative bispecific antibody for solid tumors. Convalife Pharmaceuticals' virus product pipeline includes drug research and development for a variety of infectious diseases, such as novel coronavirus, respiratory syncytial virus, monkeypox virus, yellow fever virus, etc.